Hepatitis C - Treat or Wait? A Series of Challenging Case Vignettes

Hepatitis C - Treat or Wait? A Series of Challenging Case Vignettes

Each month this blog provides readers with a link to new education-related information on hepatitis C.

You won't want to miss this learning experience over at Clinical Care Options (CCO) designed to evaluate the question of treating now-vs-waiting for future HCV therapies.  *Free registration required

Treat or Wait in HCV? A Series of Challenging Case Vignettes

In this series of case vignettes, Jordan J. Feld, MD, PhD; Michael W. Fried, MD; Mark S. Sulkowski, MD; and Stefan Zeuzem, MD, weigh the risks and benefits of treating now vs waiting for future therapies in 9 unique case scenarios.

Release Date:

January 03, 2013

Learning Objectives

Upon completion of this activity, participants should be able to:

• Analyze the likely benefits and likely drawbacks of using current HCV therapies in individual patients
• Critically appraise emerging data on investigational agents for hepatitis C and the impact on current practice
• Identify treatment-naive patients and treatment-experienced patients currently warehoused within the healthcare system who are likely to benefit from future HCV therapies
• Nurses will be better able to provide appropriate care and counsel for patients and their families

Topics covered include:

• Newly Diagnosed Patient
• Previous Peginterferon/Ribavirin Null Responder With Possible Cirrhosis
• Relapsed Genotype 3 HCV After Previous Peginterferon/Ribavirin
• Elderly Treatment-Naive Patient
• Genotype 1 Patient With Interferon-Related Depression
• Patient With HCV/HIV Coinfection
• HCV-Infected Woman of Childbearing Age
• Treatment-Naive Patient With Genotype 4 HCV
• Post–Liver Transplantation Patient With Recurrent HCV
• Conclusions

Link
Treat or Wait in HCV? A Series of Challenging Case Vignettes